Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;12(2):108-19.
doi: 10.2174/1570159X11666131120231448.

Novel Therapeutic Targets in Depression and Anxiety: Antioxidants as a Candidate Treatment

Affiliations
Free PMC article

Novel Therapeutic Targets in Depression and Anxiety: Antioxidants as a Candidate Treatment

Ying Xu et al. Curr Neuropharmacol. .
Free PMC article

Abstract

There is growing evidence that the imbalance between oxidative stress and the antioxidant defense system may be associated with the development neuropsychiatric disorders, such as depression and anxiety. Major depression and anxiety are presently correlated with a lowered total antioxidant state and by an activated oxidative stress (OS) pathway. The classical antidepressants may produce therapeutic effects other than regulation of monoamines by increasing the antioxidant levels and normalizing the damage caused by OS processes. This chapter provides an overview of recent work on oxidative stress markers in the animal models of depression and anxiety, as well as patients with the aforementioned mood disorders. It is well documented that antioxidants can remove the reactive oxygen species (ROS) and reactive nitrogen species (RNS) through scavenging radicals and suppressing the OS pathway, which further protect against neuronal damage caused oxidative or nitrosative stress sources in the brain, hopefully resulting in remission of depression or anxiety symptoms. The functional understanding of the relationship between oxidative stress and depression and anxiety may pave the way for discovery of novel targets for treatment of neuropsychiatric disorders.

Keywords: Antidepressants.; Antioxidants; Depression and anxiety; Oxidative stress; Oxidative stress pathway.

Figures

Fig. (1)
Fig. (1)
Mechanism of oxidative stress-induced neuronal damage.

Similar articles

See all similar articles

Cited by 13 articles

See all "Cited by" articles

References

    1. Kessler RC, Adler LA, Berglund P, Green JG, McLaughlin KA, Fayyad J, Russo LJ, Sampson NA, Shahly V, Zaslavsky AM. The effects of temporally secondary co-morbid mental disorders on the associations of DSM-IV ADHD with adverse outcomes in the US National Comorbidity Survey Replication Adolescent Supplement (NCS-A). Psychol. Med. 2013;8:1–14. - PMC - PubMed
    1. Skolnick P. Beyond monoamine-based therapies: clues to new approaches. J. Clin. Psychiatry. 2002;63:19–23. - PubMed
    1. Moylan S, Eyre HA, Maes M, Baune BT, Jacka FN, Berk M. Exercising the worry away: How inflammation, oxidative and nitrogen stress mediates the beneficial effect of physical activity on anxiety disorder symptoms and behaviours. Neurosci. Biobehav. Rev. 2013;37:573–584. - PubMed
    1. Jindal A, Mahesh R, Bhatt S. Etazolate, a phosphodiesterase 4 inhibitor reverses chronic unpredictable mild stress-induced depression-like behavior and brain oxidative damage. Pharmacol. Biochem Behav. 2013;105C:63–70. - PubMed
    1. Aboul-Fotouh S. Coenzyme Q10 displays antidepressant-like activity with reduction of hippocampal oxidative/nitrosative DNA damage in chronically stressed rats. Pharmacol. Biochem. Behav. 2013;104:105–112. - PubMed

LinkOut - more resources

Feedback